ORCID
- Shengxin Zhang: 0000-0001-6945-2521
- Janith Wanigasekara: 0000-0003-0962-3434
- James F. Curtin: 0000-0002-9320-9254
- Tao Zhang: 0000-0003-1079-5364
- Gemma K. Kinsella: 0000-0002-6329-5841
Abstract
Cold atmospheric plasma (CAP) has potential as a new cancer treatment tool due to its room temperature biocompatibility and possible cancer cell selectivity with low side effects. This review examines the current research stage of CAP therapy for Prostate Cancer (PCa) treatment with a focus on CAP device standardization and CAP therapy clinical translation. The current CAP preclinical data is explored through the lens of PCa cellular response, PCa cells selectivity, CAP treatment type and CAP combination therapies. Finally, building on the current preclinical data, this review proposes the potential clinical application methods of CAP at different PCa stages to promote CAP therapy into clinical use.
Keywords
CAP clinical translation, cold plasma, device standardization, plasma treatment, prostate cancer therapy
DOI Link
Publication Date
2026-01-16
Publication Title
Plasma Processes and Polymers
Volume
23
Issue
1
ISSN
1612-8850
Deposit Date
2026-01-26
Funding
Research Ireland (formerly Science Foundation Ireland) FFP award (grant number: 21/FFP-A/9189)
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Additional Links
Recommended Citation
Zhang, Shengxin; Wanigasekara, Janith; Boehm, Daniela; Curtin, James F.; Bourke, Paula; Zhang, Tao; and Kinsella, Gemma K., "Cold Atmospheric Plasma for Prostate Cancer Therapy—Potential for Clinical Translation" (2026). Research Outputs: 2025-Present. 11.
https://arrow.tudublin.ie/schfsehro/11